Open labelled, single arm, retrospective study of oral tofacitinib in vitiligo

Completed

• Conditions: Vitiligo,

• Registration Number: CTRI/2023/01/048849
• Lead Sponsor: NA

Brief Summary

Vitiligo is a chronic autoimmune condition associatedwith marked psychological distress, especially in our country owing to thedarker skin types. There is a growing need for targeted therapies in vitiligofor its effective clearance. JAK (Janus kinase) inhibitors act by inhibitingIFN (Interferon) gamma signalling which is the main cytokine implicated in melanocytedestruction(1). However, data regarding ideal dosing, efficacy and long-term safety oforal tofacitinib in the Indian population is lacking. Through our study, wehope to bridge this gap and aid in creating a standardised protocol for the useof oral tofacitinib in vitiligo.

Detailed Description

Not available

Study Timeline

• Study Completion: 2023-01-23
• Study Start: 2023-10-01
• Last Update Posted: 2024-02-24

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

All clinically diagnosed cases of different variants of vitiligo 2.Patients who were started on oral tofacitinib for vitiligo.

Exclusion Criteria

•Patients receiving other systemic immunosuppressive drugs.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess improvement in VASI from baseline	After 6 months

Secondary Outcome Measures

Name	Time	Method
1.To assess number of patients achieving VASI 50/75/90 at the end of treatment follow-up period	2.To assess change in BSA (Body Surface Area) from baseline

Trial Locations

Locations (1)

CUTIS Academy of Cutaneous Sciences; 🇮🇳 Bangalore, KARNATAKA, India

CUTIS Academy of Cutaneous Sciences

🇮🇳Bangalore, KARNATAKA, India

Dr Apoorva V Bharadwaj

Principal investigator

9686257492

veebsokplease@gmail.com